HomeAI · summaries
Storia in 3 fonti
AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercebiotech.com
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
The FDA has delayed a decision on the approval of AstraZene | The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses…
- ·
fiercepharma.com
AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday
- ·
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three years after a phase 3 flop led Takeda to withdraw…
- ·
endpoints.news
AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
AstraZeneca seeks a narrower path for failed antibody; Imfinzi and Tremfya label expansions
- ·
ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. | After winning a broader FDA label in metastatic castration-resistant…
- ·
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t…